ClinicalTrialStartPulse / report
Innovent Biologics (Suzhou) Co. Ltd.: Phase 2 study closed enrollment, 203 enrolled (Melanoma)
Innovent Biologics (Suzhou) Co. Ltd.: Phase 2 study closed enrollment, 203 enrolled (Melanoma). Its enrollment of 203 is above the median of 80 (77th percentile). Dated 2 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-03, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 203 · 77th percentile of 8,570 ClinicalTrialStartPulse records · 2.5x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy |
| NCT ID | NCT06797297 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Melanoma |
| Intervention types | biological |
| Target enrollment | 203 |
| Site countries | China |
| Posted | 2025-01-28 |
| Planned start | 2025-02-24 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |
| enrollment percentile | 77th of 8,570 (median 80, 2.5x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Innovent Biologics (Suzhou) Co. Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Innovent Biologics (Suzhou) Co + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-11-02
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Tue, 03 Nov 2026 05:11:05 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Innovent Biologics (Suzhou) Co. Ltd. and 6,377 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,377
- Innovent Biologics (Suzhou) Co. Ltd.'s enrollment: 77th percentile of 8,570 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,275,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 203 participants planned.
What is the ClinicalTrialStartPulse record for Innovent Biologics (Suzhou) Co. Ltd.?
Innovent Biologics (Suzhou) Co. Ltd.'s Phase 2 study (NCT06797297) in Melanoma, first posted 2025-01-28: enrollment closed (active, not recruiting) (2026-11-02), in an update posted 2026-11-02.
How does Innovent Biologics (Suzhou) Co. Ltd. compare to other ClinicalTrialStartPulse records?
Its enrollment of 203 sits in the upper half (77th percentile) of 8,570 records; the median is 80. It is fresh: dated 2 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Innovent Biologics (Suzhou) Co. Ltd. vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | NONUS | 203 | 77th | 2026-11-02 |
| Pelage Pharmaceuticals, Inc. | NONUS | 200 | 77th | 2026-10-30 |
| Merck Sharp & Dohme LLC | NONUS | 290 | 82nd | 2026-11-02 |
Related records
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: Outside the US only
How to monitor Innovent Biologics (Suzhou) Co. Ltd. and peer phase 2 records
Get new ClinicalTrialStartPulse records like Innovent Biologics (Suzhou) Co. Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.